0NZU.LSE Zealand Pharma A/S
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0NZU.LSE undervalued?
Graham numberThe Graham number of Zealand Pharma A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zealand Pharma A/S fundamental analysis
No fundamental analysis for Zealand Pharma A/S yet.
Zealand Pharma A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas sys…
Full company profileFinancial statements of Zealand Pharma A/S are not available yet.
Zealand Pharma A/S dividends
Zealand Pharma A/S has not paid dividends in the last 4 fiscal years.
Who owns Zealand Pharma A/S
- Insiders 0.53%
- Institutions 39.96%
- Public & others 59.51%
- Free float 59.4M
Zealand Pharma A/S company profile
- Company name
- Zealand Pharma A/S
- Ticker
- 0NZU.LSE
- ISIN
- DK0060257814
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 578
- Fiscal year end
- December
- Address
- Sydmarken 11, Søborg, Denmark, 2860
- Phone
- 45 88 77 36 00
- Website
- zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Zealand Pharma A/S management
10- Mr. Adam Sinding Steensberg M.D.President & CEO · born 1974
- Ms. Henriette WennickeEVP & CFO · born 1983
- Mr. Ivan Mourits MollerExecutive VP & COO
- Mr. Utpal SinghExecutive VP & Chief Scientific Officer · born 1974
- Mr. Eric RojasVP & Head of Investor Relations
- Mr. Ravinder Singh ChahilEVP & General Counsel · born 1968
- Ms. Christina Sonnenborg BredalExecutive VP & Chief People Officer · born 1985
- Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular Pharmacology
- Dr. David M. Kendall M.D.Executive VP, Chief Medical Officer & Head of R&D · born 1961
- Mr. Eric CoxExecutive VP & Chief Commercial Officer · born 1967